<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161287</url>
  </required_header>
  <id_info>
    <org_study_id>JingSun</org_study_id>
    <nct_id>NCT04161287</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE</brief_title>
  <official_title>Comparison of Efficacy in Stereotactic Body Radiation Therapy (SBRT) of Hepatocellular Carcinoma ≤5 cm With or Without Transcatheter Arterial Chemoembolization (TACE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing 302 Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare efficacy and adverse reactions of hepatocellular carcinoma
      participants (≤5cm) who receive stereotactic body radiation therapy with or without
      transcatheter arterial chemoembolization.The investigators will optimize the combined
      treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall
      survival rates, progression-free survival rates and local control and adverse reaction
      occurrence rates in the two groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2019</start_date>
  <completion_date type="Anticipated">January 11, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rates</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 36 months</time_frame>
    <description>OS is calculated starting from the date of SBRT to the date of the final follow-up or demise of the patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival rates</measure>
    <time_frame>From date of randomization until the date of disease progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>PFS is estimated starting from the date of SBRT to the date of disease progression or patient death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local control rates</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>LC is defined starting from the date of SBRT to the date of treated-lesion progression or patient death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiation-induced liver injury rates</measure>
    <time_frame>From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reaction</measure>
    <time_frame>From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Small Hepatocellular Carcinoma</condition>
  <condition>Stereotactic Body Radiation Therapy</condition>
  <condition>Transcatheter Arterial Chemoembolization</condition>
  <arm_group>
    <arm_group_label>SBRT with TACE</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT alone</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transcatheter arterial chemoembolization</intervention_name>
    <description>The hepatocellular carcinoma patients (≤5cm）who received SBRT are devided into two groups: with TACE and SBRT alone.</description>
    <arm_group_label>SBRT with TACE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        hepatocellular carcinoma patients whose lesion diameter ≤ 5.0 cm
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the
             international guidelines for the management of HCC or by pathology

          -  single lesion and longest tumor diameter ≤ 5.0 cm

          -  CP-A or B classification

          -  Eastern Cooperative Oncology Group (ECOG) score 0-1;

          -  distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are
             more than 5 mm

          -  unsuitable for other therapies, such as patients with heart disease, uncontrolled
             diabetes, uncontrolled hypertension, etc.

          -  rejecting other therapies such as resection, liver transplantation, etc.

          -  platelet count≥50 × 109/L, white blood count≥1.5 × 109/L

          -  patients infected with hepatitis B virus who are treated with adefovir or entecavir;
             patients infected with hepatitis C virus whose HCV DNA are negative.

        Exclusion Criteria:

          -  tumor thrombus

          -  lymph node involvement

          -  extrahepatic metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuezhang Duan, PH.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The fifth medical center of PLA general hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Sun, Master</last_name>
    <phone>+8613718681094</phone>
    <phone_ext>+8613718681094</phone_ext>
    <email>519299998@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xuezhang Duan, PH.D</last_name>
    <phone>8613621386161</phone>
    <phone_ext>8613621386161</phone_ext>
    <email>duanxuezhang2006@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Fifth Medical Center of PLA General Hospital (Beijing 302 hospital)</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Sun</last_name>
      <phone>+8613718681094</phone>
      <phone_ext>+8613718681094</phone_ext>
      <email>519299998@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Xuezhang s Duan</last_name>
      <phone>8613621386161</phone>
      <phone_ext>8613621386161</phone_ext>
      <email>duanxuezhang2006@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Sun J, Zhang T, Wang J, Li W, Zhang A, He W, Zhang D, Li D, Ding J, Duan X. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm). BMC Cancer. 2019 Aug 28;19(1):846. doi: 10.1186/s12885-019-6063-9.</citation>
    <PMID>31455251</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang T, Sun J, He W, Li H, Piao J, Xu H, Duan X. Stereotactic body radiation therapy as an effective and safe treatment for small hepatocellular carcinoma. BMC Cancer. 2018 Apr 20;18(1):451. doi: 10.1186/s12885-018-4359-9.</citation>
    <PMID>29678159</PMID>
  </results_reference>
  <results_reference>
    <citation>Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, Tang MY, Jiang HY, Lian ZP, Hou EC, Liang P. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma &gt;5 cm. BMC Cancer. 2016 Nov 3;16(1):834.</citation>
    <PMID>27809890</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019 Mar;28:228-235. doi: 10.1016/j.suronc.2019.01.006. Epub 2019 Jan 29.</citation>
    <PMID>30851906</PMID>
  </results_reference>
  <results_reference>
    <citation>Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012 Apr;56(4):886-92. doi: 10.1016/j.jhep.2011.10.021. Epub 2011 Dec 13.</citation>
    <PMID>22173160</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CyberKnife</keyword>
  <keyword>SBRT</keyword>
  <keyword>TACE</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

